Albumedix
Presence
Novozymes is one of the...
Novozymes is a company listed under the stock ticker NVZMY (DK).
Novozymes has a direct presence in 2 countries.Novozymes has 3 subsidiaries including Albumedix, Chr. Hansen and Novonesis.
They are in:
- Chemicals50%
- Pharmaceuticals25%
- Other25%
Acquisition, funding and merger involving Novozymes.
- Novozymes and Chr. Hansen have merged (posted on January 29 2024)..
Executives
View the org chart displaying its 12 main executives
Most searched biographies at Albumedix
- Jonas Moeller, Chief Executive Officer and Director
- Don deBethizy, Chairman of the Board
- Peter Rosholm, Director
Popular executive movements at Novozymes
- Kevin Lane has joined the company as Director (posted on March 5 2024).
- Lise Kaae has joined the company as Director (posted on March 5 2024).
- Jesper Brandgaard has joined the company as Vice Chairman of the Board (posted on March 5 2024).
Click here to view some more movements at Novozymes
Create your alert
to follow the executive moves at Albumedix.
Pharmaceuticals
Novozymes has 1,868 competitors including Pfizer (United States (USA)), Sanofi (France) and Johnson & Johnson (United States (USA)).
Popular M&A news in Pharmaceuticals
- AstraZeneca has announced the acquisition of Fusion Pharma (posted on March 23 2024).
- AstraZeneca has announced the acquisition of Amolyt Pharma (posted on March 19 2024).
- Frontier Medicines has just announced a $80 Million fundraising (posted on February 27 2024).
Popular contacts in Pharmaceuticals
News
Press releases by Albumedix
- Solis BioDyne | Eliminating inconsistent raw materials to deliver dependable quality and consistency in their latest product
- Our Insights from Advanced Therapies Week
- 2024 Advanced Therapies
- Vaccine Partner Valneva receives FDA approval for the World’s first chikungunya vaccine using Albumedix’ Recombumin®
- Albumedix Ltd. Appoints Joanna Hay as Vice President of Commercial Operations
- Has COVID-19 changed the future of pharmaceutical regulation?
- Albumedix and Valneva Expand Collaboration to Include Newly Approved Inactivated COVID-19 Vaccine
- Albumedix and Heartseed announce Recombumin® as a critical excipient in the manufacture of Heartseed's HS-001 investigational cell therapy as its first in-human trial commences
- Sartorius completes acquisition of Albumedix
- Sartorius to acquire Albumedix, creating a powerhouse for innovative advanced therapy solutions
- View more press releases Close
Social media about Albumedix
- Albumedix on Wikipedia, Google News & Yahoo Finance
- Albumedix on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Joanna Hay 
